Partial List of Poster Titles

 

  • BellBrook Labs: Determination of Drug Residence Times in a HTS Format Using Transcreener ADP2 Kinase Assay
  • BioSolveIT, Inc.: Focused Library Design for the 21st Century
  • Brigham and Women's Hospital: Brevican-Specific Peptides for the Development of Next-Generation Therapeutics for Glioblastoma
  • C4X Discovery: Ligand Conformational Analysis Enabling Improved Nrf2 Activators
  • Cayman Chemical Company: SAM-SCREENER™: Versatile Fluorescent Molecular Probes for Histone Methyltransferases
  • ChemDiv, Inc.: Design and Synthesis of PPI-Focused Library of Natural-Product-Based Compounds
  • ChemDiv, Inc.: Underexplored Chemical Space: Medium- and Large- Sized b-Alanine Based Lactams
  • Chemical Computing Group: Exploring EGFR Kinase-Ligand Interactions for Optimizing Dual Action Inhibitors
  • Chemical Computing Group: Exploring the Role of Solvation in Drug Design and Optimization
  • Circle Pharma, Inc.: Computer-Aided Design of Permeable Macrocycles
  • CMDBioscience, Inc.: The Application of CMDInventus to Design Novel Peptides for Protein-Protein Interactions
  • EDASA Scientific: Isatine-Based Fragments as a Research Tool for Generating Metallo-Protease Oriented Compound Arrays
  • Ensemble Therapeutics: Highly Potent and Selective Macrocyclic Inhibitors of Indoleamine 2,3-Dioxygenase (IDO)
  • Frontier Scientific, Inc.: Exploring Chemical Space and Commercial Compounds for Kinase Inhibitors and Fragments
  • Galen Biotechnologies, LLC: Translating a Helical Interaction Code into Small-Molecules
  • Genentech, Inc.: Case Study on DLK Inhibitors for the Treatment of Neurodegenerative Diseases
  • Gwangju Institute of Science and Technology: Design, Synthesis and Evaluation of 2,5-Dioxoimidazolidine Based Conformationally Constrained Analogues of KN62 as Novel P2X7 Receptor Antagonists
  • Hypha Discovery Ltd.: Biocatalytic C-H Activation of the JAK Inhibitor Ruxolitinib
  • Institute of Organic Chemistry and Biochemistry: Structure Guided Inhibitor Design of the Lipid Kinase PI4KB Yields Subnanomolar Inhibitors
  • Kalexsyn, Inc.: Generation of Broad-Spectrum Antifungal Drug Candidates from the Natural Product Compound Aureobasidin A
  • Key Organics: Building a Diverse and Experimentally-Curated Fragment Library
  • Korea Research Institute of Bioscience and Biotechnology: Protein-Ligand Binding Site Recognition Using Local Sequence Alignment and Geometrical Pocket Search
  • Life Chemicals, Inc.: Fragment Screening Libraries
  • Life Chemicals, Inc.: PPI and Epigenetic Targeted Libraries From Life Chemicals
  • Life Chemicals, Inc.: PPI Inhibitor Screening Compound Libraries
  • Medical & Biological Laboratories, Co., Ltd.: A Novel Method for Visualizing Protein-Protein Interactions in Living Cells; For Evaluating Plasma Membrane Penetration and Activity of PPI Modulators Simultaneously
  • Merck Research Laboratories: Synthesis of Macrocyclic Peptidomimetics via Pd-Catalyzed Macroamination Reactions
  • Midwestern University: Aspartyl(Asparaginyl)-Beta-Hydroxylase Inhibitors for the Treatment of Hepatocellular Carcinoma
  • Monogram Biosciences: Novel Assays to Support Human Respiratory Syncytial Virus Drug and Vaccine Development
  • Nanomedical Diagnostics, Inc.: AGILE Sensors Test Molecular Interactions in Challenging Samples for Drug Discovery
  • National Taiwan University: Design, Synthesis and Biological Evaluation of Multifunctional Molecules as Potential Anti-Alzheimer's Agents
  • National Health Research Institutes: Design and Discovery of Novel Potent Epidermal Growth Factor Receptor (EGFR) Inhibitors for NSCLC
  • National Health Research Institutes: Design and Synthesis of Indazole-Based Derivatives as Aurora Kinases Inhibitors
  • National Health Research Institutes: Fragment-Based Library: Design and Synthesis of 4-Amonopyrimidine Derivatives as BTK Inhibitors Using High Throughput Parallel Synthesis
  • OP Bio Factory Co., Ltd.: Medium Molecular Weight Natural Product Library as a Source for Discovery of Orally Bioavailable Protein-Protein Interaction Targeted Drugs
  • Optibrium Ltd.: Bridging the Dimensions: Seamless Integration of 3D Structure-Based Design and 2D Structure-Activity Relationships to Guide Medicinal Chemistry
  • PerkinElmer: High Throughput Quantitation of Cytokine Biomarkers Using Lance Ultra® TR-FRET Assays
  • PerkinElmer: Novel Bromodomain and Extra Terminal Domain (BET) Family Bromodomain Assays Utilizing AlphaLISA® Technology
  • PerkinElmer: Simultaneous Detection of Total and Phosphorylated Protein in Cellular Kinase Assays Using Alpha SureFire® Ultra™ Multiplex Technology
  • Philipps-University Marburg: A 3D-Diverse Fragment Library for Crystallographic Screening and Drug Discovery
  • Promega Corporation: Detection of JumonjiC Domain-Containing Histone Demethylase Activities With a Homogeneous Bioluminescent Succinate Assay
  • Promega Corporation: Kinase Target Engagement & Drug Residence Time Using BRET
  • Promega Corporation: Measuring Intracellular Target Engagement via BRET at HDAC and BRD
  • Promega Corporation: Profiling FDA-Approved Small Molecule Kinase Inhibitors Using Bioluminescent Kinase Profiling Systems
  • Promega Corporation: Universal Homogenous Bioluminescent Assay That Monitors the Activity Various Classes of Methyltransferases In Vitro
  • Schrodinger, Inc.: Large Scale Validation of Mixed-Solvent Simulations to Assess PPI Druggability
  • Stanford University: Identification of Novel Small Molecule Inhibitors of IgE:FcεRI Protein-Protein Interactions
  • Takeda California: Increasing SPR's Impact on Drug Discovery by Minimizing Mass Transport Effects
  • Technische Universität Dresden: Applying DNA-Encoded Chemical Library Technology to Fragment-Based Drug Discovery
  • UCB: Kinetic FRET Assays for PPI Drug Discovery
  • Univ of Toronto: Small-Molecule Inhibitors with Potent Activity in STAT3-Overexpressing Brain Tumour Stem Cells, TKI-Resistant CML Cells and Breast Cancer Cells
  • University of Cambridge: Achieving Small-Molecule Induced Disruption of CK2β Dimer Using a Fragments-Based Approach
  • University of Hong Kong: Identification of a Small-Molecule Inhibitor of Influenza Virus via Disrupting the Subunits Interaction of the Viral Polymerase
  • University of Muenster: Transporters of the Multidrug Resistance: Reconstitution into Proteoliposomes and Biophysical Characterisation
  • University of Muenster: Use of Nanoparticles to Cross the Blood Brain Barrier
  • University of Pennsylvania: Structure-Based Design of Brain Penetrant Inflammation Inhibitors for Alzheimer's Disease
  • University of Puget Sound: Development of Novel Arsenic and Thiourea Catalysts for Direct Amidation of Carboxylic Acids and Amines
  • University of Tokyo: Ribosome-Mediated Site-Specific Incorporation of Dipeptides and Dipeptidomimetics into Proteins
  • Virginia Commonwealth University: An In Vitro Selection Approach for Optimizing Macrocyclic Peptide Scaffolds
  • ZoBio BV: A New Approach to Inhibiting Lysine Methyl Transferases

 


PRESENT A POSTER AND SAVE $50! 

Dedicated poster sessions for Symposia and Conference Programs. 

 

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by March 11, 2016.

Register online, or by phone, fax or mail.  Please indicate that you would like to present a poster.  Once your registration has been fully processed, we will send an email with a unique link and instructions for submitting your abstract using our online abstract submission tool.  Please see below for more information.

Reasons you should present your research poster at this conference:

  • Your poster will be seen by our international delegation, representing leaders from top pharmaceutical, biotech, academic and government institutions
  • Receive $50 off your registration 
  • Your poster will be automatically entered into the main conference poster competition (see below for details) 
  • Your poster abstract will be published in our conference materials  

Poster Competition Details: (main conference)
•         Poster must be submitted by deadline, March 11th
•         Two poster winners will be selected based on criteria below
•         Cash prizes will be awarded on last day of regular (not including the symposia) event -- April 21, Thursday, at end of lunch in exhibit hall. If winner is not present, award check will be mailed.

First round of selection will be based on submitted abstracts and be judged by CHI Conference Directors and their Scientific Advisors. The following criteria will be used:
•         Clarity of abstract
•         Novelty of data
•         Significance for drug discovery

Final round will be judged on-site based on:
•         Aesthetic quality and visual clarity of poster
•         Clear and engaging oral explanation of poster

 

You must be registered for a Symposium to present at the Symposia Poster Session; You must be registered for a Conference Program to present at the Conference Program Poster Session. 
Each poster is limited to one poster session.  Conference Program posters must be relevant to the main conference topics.  Symposia posters must be relevant to your selected symposium. 

* CHI reserves the right to publish your poster title and abstract in various marketing materials and products.
** One poster discount per registration.
*** There are no posters for the Training Seminar

Note: Posters should be portrait orientation, with maximum dimensions of 36 inches wide (3 feet) x 48 inches high (4 feet). 

Click here for poster instructions and guidelines.

Poster inquiries: jring@healthtech.com